Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

The Trump administration has introduced legislation outlining plans for deep cuts to Medicaid, possibly impacting millions of ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

Vir Biotechnology announced the data during the EASL conference on Friday. Image credit: Shutterstock / T Schneider. Vir ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with ABO21009, aimed at treating rheumatoid arthritis (RA ...